Regeneron Pharmaceuticals
stock was tumbling after the medicine maker reported lower sales of its Eylea treatment than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion. The consensus call among analysts tracked by FactSet was for $1.64 billion, while the year-earlier figure was $1.55 billion.
(Makes clear no remark from Thyssenkrupp (ETR:) Metal, not Thyssenkrupp in paragraph 3) BERLIN (Reuters) -Impartial specialists trying into the...
This text was written byComply withAfter 15 years working within the monetary sector, performing evaluation and judging danger administration at...
Maharashtra & Jharkhand Election Outcomes Winners Full Listing: On November 23, the Bharatiya Janata Social gathering-headed Mahayuti alliance received the race...
Within the run-up to the September presidential election—at which Wickremesinghe was defeated—Dissanayake was important of the bailout, particularly its inflexible...
For the previous two years, Uddhav Thackeray has been saying that Eknath Shinde walked away with 13 members of parliament...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
